Wedbush Reiterates Outperform on BridgeBio Oncology, Maintains $25 Price Target

Benzinga · 11/25/2025 14:08
Wedbush analyst David Nierengarten reiterates BridgeBio Oncology (NASDAQ:BBOT) with a Outperform and maintains $25 price target.